98
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?

, , , , , , & show all
Pages 381-388 | Published online: 10 Dec 2015

Figures & data

Table 1 Pathological complete response (pCR) rates and its association to clinicopathological variables

Table 2 Changes in pre- and post-NACT IHC4

Figure 1 Kaplan–Meier estimates of relapse-free survival.

Note: (A) shows the predicted relapse-free survival (RFS) (in months, x-axis) for the three groups with differential estrogen receptor (ER) Allred scores (A=0–2, B=3–5, C=6–8); hazard ratio: Pre_chemo_ER_Allred_A 8.145, confidence interval 1.59–40.85, P<0.01; Pre_chemo_ER_Allred_B 10.243, confidence interval 1.97–57.97, P,0.01. C is the reference. (B) shows the RFS (in months, x-axis) for the three groups of progesterone (PR) Allred scores (A=0–2, B=3–5, C=6–8). There was statistically significant difference in RFS predicted for both the ER and PR groups (P=0.002 and P=0.013, respectively).
Figure 1 Kaplan–Meier estimates of relapse-free survival.

Figure 2 Kaplan–Meier estimates of relapse-free survival.

Note: Relapse-free survival (in months, x-axis) predicted for the four molecular subtypes.
Abbreviations: LA, luminal A; LB, luminal B; HE, HER2 enriched; TN, triple negative.
Figure 2 Kaplan–Meier estimates of relapse-free survival.

Figure 3 Kaplan–Meier estimates of relapse-free survival.

Note: Relapse-free survival (in months, x-axis) in groups with pathological complete response (pCR), lower Ki-67 and stable/high Ki-67 postchemotherapy.
Figure 3 Kaplan–Meier estimates of relapse-free survival.

Figure 4 Kaplan–Meier estimates of relapse-free survival.

Notes: Relapse-free survival (in months, x-axis) of tumors that changed hormone receptor from positive to negative versus from negative to positive. Log-rank P=0.06 (hazard ratio [HR] =0.2489, 95% confidence interval 0.18–1.09).
Figure 4 Kaplan–Meier estimates of relapse-free survival.